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Abstract
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease and related
hospitalization of young children in least developed countries. Individuals are repeatedly infected, but it is the first
exposure, often in early infancy, that results in the vast majority of severe RSV disease. Unfortunately, due to
immunological immaturity, infants are a problematic RSV vaccine target. Several trials are ongoing to identify a
suitable candidate vaccine and target group, but no immunization program is yet in place.
Methods: In this work, an individual-based model that explicitly accounts for the socio-demographic population
structure is developed to investigate RSV transmission patterns in a rural setting of Kenya and to evaluate the
potential effectiveness of alternative population targets in reducing RSV infant infection.
Results: We find that household transmission is responsible for 39% of infant infections and that school-age children
are the main source of infection within the household, causing around 55% of cases. Moreover, assuming a
vaccine-induced protection equivalent to that of natural infection, our results show that annual vaccination of
students is the only alternative strategy to routine immunization of infants able to trigger a relevant and persistent
reduction of infant infection (on average, of 35.6% versus 41.5% in 10 years of vaccination). Interestingly, if vaccination
of pregnant women boosts maternal antibody protection in infants by an additional 4 months, RSV infant infection
will be reduced by 31.5%.
Conclusions: These preliminary evaluations support the efforts to develop vaccines and related strategies that go
beyond targeting vaccines to those at highest risk of severe disease.
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Background
Respiratory syncytial virus (RSV) is characterized world-
wide by recurrent epidemics [1-4] and represents a
leading cause of hospitalization of young children in
least developed countries (LDCs) [5-7], where the vast
majority of severe disease (and deaths) caused by RSV
occurs [6]. Indeed, RSV can be considered one of the
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predominant viral pathogens among hospitalized infants
[5,7].
Primary RSV infection usually arises in the first two
years of life, and repeated reinfections occur through-
out life [3,4,8,9]. However, most severe disease occurs
among individuals infected during their first year of
life, usually as a consequence of primary RSV infection
[3-6,8,10-12].
During the 1960s, trials of a formalin-inactivated RSV
vaccine administered to RSV-naive US children led to
enhanced lower respiratory tract disease (LRTD) follow-
ing natural RSV challenge in the immunized group [13].
After the failure of this immunization experience, differ-
ent live attenuated RSV vaccines were evaluated in clinical
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trials in adults, young children, and infants, but none has
gone beyond early-stage clinical trials or been licensed yet
[14]. Indeed, although the highest priority target popula-
tion for vaccine development is the RSV-naive child [3,14],
clinical evaluation of various vaccine candidates has met
a range of problems related to the lack of immunolog-
ical maturity and vaccine tolerance in this vulnerable
age group that has thwarted progress [13,14]. It is still
unclear which vaccine would result in an effective pro-
tection against RSV infection and RSV-associated disease,
and which, if any, would be suitable for being administered
safely to infants.
The first objective of this work is to investigate, through
mathematical modeling techniques, RSV transmission
patterns in a low-income setting in order to realisti-
cally describe and understand the transmission chain
leading to RSV infant infection, which causes most of
RSV-associated serious disease. An empirical basis for
this work is household studies [9,15] that have sug-
gested a significant role of school-age children in intro-
ducing and spreading RSV infection in the household.
The second objective of this work is to assess which
immunization strategies can be effective in preventing
RSV at a population level. More specifically, we aim to
identify which subgroup of the population should be
targeted, and with which schedule, in order to achieve
an effective reduction of RSV infection rates in those
age groups at highest risk of severe disease. The explo-
ration of the various alternatives might provide useful
indications for current and future vaccine development
efforts by assessing which age targets can be consid-
ered as valuable for interrupting the chain of transmis-
sion and reducing infection rates in the first year of
life.
Methods
Individual-based transmission models of infectious dis-
eases represent a powerful tool to evaluate and optimize
interventions aimed at controlling human infectious dis-
eases [16-19]. The need for detailed epidemiological and
socio-demographic data to calibrate micro-simulation
models makes the implementation of similar tools for
LDCs a modeling challenge. In this work, a highly detailed
socio-demographic and disease transmission model is
developed and used to investigate the RSV transmission
dynamics in a predominantly rural location of a low-
income setting of coastal Kenya, representing an illustra-
tive case of a high-burden region with limited financial
resources. Specifically, the RSV infection process is simu-
lated over a synthetic population of individuals structured
in households and schools that is consistent with the
main descriptive statistics of the Kenyan population as
reported in the Demographic and Health Surveys (DHS,
[20], accessed Jul 2014).
Modeling socio-demographic characteristics of a
sub-Saharan population
The simulated synthetic population consists of about
200,000 individuals, all explicitly represented in the model
and grouped into households and primary schools. In
particular, the simulated households structure mirrors
existing generational age gaps between parents and their
children and the observed complex heterogeneity in the
Kenyan population, such as the co-location of several
generations (up to four) within a single household. This
was achieved through intensive use of available socio-
demographic data for Kenya from the Demographic and
Health Surveys (DHS) and other available data. DHS data
were used to randomly assign age and co-locate individ-
uals in households. Individuals were assigned to schools
according to the age-specific school attendance rates com-
puted by using the DHS dataset and school size distribu-
tion as provided by theOpenKenya dataset ([21], accessed
Jun 2014). Annual fertility rates by age were computed
according to the DHS statistics for the years 2002-2008.
Annual mortality rates by age were obtained from the
World Population Prospects of the United Nations ([22],
accessed Jun 2014). Themodel was capable of reproducing
the observed distributions of both household and school
size, the age structure of the Kenyan population and the
age-specific school attendance rates. Further details on
the procedure used for generating the synthetic popu-
lation and the validation process against the available
socio-demographic data are provided in Additional file 1.
RSV transmission model
The epidemiological model distinguishes between pri-
mary RSV infection, related to the first exposure to RSV
in life, and subsequent infections. In agreement with epi-
demiological evidence [4] and with past modeling works
[23-25], temporary (waning) immunity is combined in our
model with a lifelong reduced susceptibility of individuals
who have already experienced a first RSV infection.
The transmission process is simulated over the syn-
thetic population described above, through a stochastic
individual-based model that reflects the natural history
of RSV infection. After birth, individuals are initially fully
protected against RSV infection by the passive transfer
of maternal-specific immunity. At each time step of the
simulation, individuals protected by maternal antibodies
become susceptible to the infection with probability μt,
where t is the length of the time step (here, t = 1 day)
and 1/μ is the average duration of maternal protection,
which is assumed to be 4 months [26]. Each susceptible
individual can become infected through infectious con-
tacts with household members, schoolmates (if attending
a school), or through encounters in the general commu-
nity. The latter accounts for all contacts not occurring
within household or school settings, for example, at the
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workplace, on public transportation, at markets, and at
shops. Specifically, at any time step t of the simulation, a
susceptible individual i has a probability pi = 1− e−λi(t)t
of being infected, where λi(t) is the instantaneous risk of
infection. We assume homogeneous mixing between all
individuals who belong to the same setting, and thus the
risk of infection λi(t) can be computed for each individual










• i, hi, si identify, respectively, an individual, his/her
household, and (if any) his/her school;
• I, Ihi , Isi represent the number of infectious
individuals in the population, in household hi, and in
school si;
• N ,Nhi ,Nsi represent the number of individuals in the
population, in household hi and in school si;
• ρi is the susceptibility to infection of individual i,
which depends on the infection history of i ; ρ = 1 if i
has never been infected and ρ = x < 1 if i has
already experienced an RSV infection;
• β is the setting-independent RSV transmission rate.
After each infection episode, infectious individuals
recover with probability γt, where 1/γ is the average
length of the infectious period, which is assumed to be
11 days, in agreement with the estimated average dura-
tion of shedding given in the literature [27]. Recovered
individuals are initially fully protected against reinfec-
tion, but become susceptible (at least partially) again with
probability δt, where 1/δ is the average duration of
the temporary complete immunity against reinfection. At
the beginning of the simulated epidemic, the fraction of
individuals by age who had already experienced an RSV
infection in the past was approximated by the age-specific
fraction of seropositive individuals as observed in the
cohorts followed between 2002 and 2005 [4]. Incidence
rates of primary and repeated RSV infections by age were
also derived from the same individuals and used to cali-
brate our model. Such approximations can be justified by
the evidence that the RSV serological profile does not sig-
nificantly change over a short period of time (from 2002 to
2005). Monthly importation of new RSV cases is consid-
ered in model simulations in order to account for a popu-
lation that is not fully closed to RSV infections generated
outside of the study area (see Additional file 1). Imported
cases are randomly chosen in the population of suscepti-
ble resident individuals. The Kenyan school calendar year
is considered in model simulations; that is, school enroll-
ment is implemented at the beginning of January and
school closures are implemented in April, August, and
December (World Data on Education [28], accessed Jun
2014); RSV transmission in school is interrupted during
these periods (that is, we assume Isi(t)/Nsi(t) = 0).
We assume homogeneous mixing among individuals
who share the same setting, and a setting-independent
transmission rate. This means that: 1) each individual has
contacts at randomwith all the individuals who share with
her/him the same setting (for example, the same school
or the same household); 2) the probability that a specific
individual i has a contact with a specific individual j is
inversely proportional to the setting size; 3) each contact
between a susceptible and an infected individual generates
a new infection with a probability that does not depend on
the setting where the contact occurs.
A sensitivity analysis is reported in Additional file 1,
where we assume three distinct transmission rates, one for
each of the three distinct settings considered in the model:
household, school, and general community.
It is shown that the set of strategies resulting in effective
prevention of RSV infant infection does not change when
the assumption of a setting-independent transmission rate
is relaxed.
Model calibration
The transmission model is calibrated by performing
a Bayesian statistical analysis [29,30] of primary and
repeated infection incidence data collected from a birth
cohort of 635 children in Kilifi, Kenya, each of whom
was followed over three consecutive RSV seasons (from
2002 to 2005) [3,4,31]. The model has the following free
parameters: 1) the RSV transmission rate β ; 2) the aver-
age duration of complete immunity generated from each
infection event 1/δ; 3) the relative susceptibility to RSV
reinfection once temporary immunity has waned x.
The posterior distributions of the free model param-
eters were explored by Markov chain Monte Carlo
(MCMC) sampling applied to the likelihood of observing
the age-specific RSV incidence, stratified by primary and
repeated infections, in a population which reflects the Kil-
ifi cohort study [4]. Specifically, by assuming that for each
considered age group the number of observed RSV cases











1 − pj(a; θ)
)n(a)−kj(a)
where index j runs over the two types of infection (pri-
mary and repeated), index a runs over the age groups
considered in the cohort study (0-5, 6-11, 12-17, 18-23,
24-30 months), n(a) is the number of individuals of age
a at the beginning of the interval considered, kj(a) is the
number of infections of type j reported at age a, and
pj(a; θ) is the probability of type j infection for individu-
als of age a as predicted by the model simulations with
parameter set θ = (β , δ, x). Notice that if some children
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acquire both primary and repeated infections at age a,
both infection episodes are considered in the computation
of k and p. Details on model calibration are reported in
Additional file 1.
Vaccination
Vaccinated individuals (including those who have already
experienced RSV) are assumed to gain a temporary full
protection against infection. Similarly to natural infection,
once temporary vaccine protection has waned, immu-
nized individuals are assumed to become susceptible to
RSV infection.
Given the unknown efficacy of potential RSV vaccines
and the uncertainties surrounding future coverage, we
consider three scenarios on the percentage of successfully
immunized individuals in the target population, namely,
100%, 80%, and 60%. Also, three different scenarios on
mean duration of vaccine protection against RSV infec-
tion are evaluated: 4, 6, and 12 months.
We first considered a routine universal vaccination
strategy at 3 months of age, with and without a catch-up
campaign targeting individuals between 3 months and 15
years of age for the first year of the program. Immuniza-
tion at 3 months of age is simulated in order to evaluate
potential benefits resulting from the availability of a vac-
cine suitable for being administered to infants. Routine
immunization of infants is assumed to occur within the
third month of age of each child.
The second targeted age group was school-age children.
Specifically, a one-off vaccination at first school enroll-
ment is evaluated, with and without a catch-up campaign
in the first year of the program targeting only students
of primary schools. Potential effects of repeating the vac-
cination campaign annually, as recently implemented in
the UK [32] for controlling seasonal influenza, are also
explored by assuming all primary students as our annual
target population. The effects of targeting only students
cohabiting with infants are also explored. Vaccination at
school enrollment, vaccination of all students, and all
catch-up strategies are implemented on the first day of
January.
Thirdly, in line with renewed interest in targeting preg-
nant women for RSV vaccination [14] (see also [33],
accessed Jun 2014), we explored this strategy under two
different assumptions: a) the vaccine has no direct pro-
tective effect on the offspring of immunized women who
will benefit only indirectly from herd immunity effects;
b) the vaccine administered to pregnant women pro-
vides a longer duration of maternal antibody protection
against RSV infection to their newborns. In the latter
case we assume that vaccination of pregnant women
extends the duration of natural maternal protection pro-
vided by unvaccinated mothers (which is assumed to be 4
months) to 5, 6, and 8 months, representing, respectively,
an additional 1, 2, and 4 months protection due to vaccine
boosting. Vaccination of pregnant women is performed at
each birth.
Results and discussion
RSV transmission in the Kilifi cohort: data and simulation
In agreement with previous findings [4], our estimates
suggest that RSV infection generates a period of com-
plete immunity to reinfection lasting, on average, 6.56
months (95% CI 1.80,14.7), after which little resistance
to repeated infection remains (the relative susceptibility
is estimated to be, on average, 0.88 95% CI 0.41,0.99).
Model predictions on the age-specific incidence of pri-
mary and repeated RSV infection based on the estimated
posterior distribution of the model parameters robustly
capture the observed patterns (see Figure 1). In particu-
lar, our results show that primary incidence peaks before
12 months of age (see Figure 1a), with young infants (<6
months) suffering a lower risk of RSV infectionmainly due
to passive transfer of maternal-specific immunity [26,34].
Primary incidence decreases with age for children older
than 1 year, for which a larger fraction of individuals has
already experienced their first RSV infection episode (see
Figure 1c). On the other hand, repeated RSV infection
incidence among young children (<30 months) increases
steadily with age (see Figure 1b). The predicted age-
specific RSV serology, in line with the observed values,
shows that almost all individuals have already experienced
at least one RSV infection at 2 years of age (see Figure 1c);
the estimated median age at first infection is, on average,
16.0 months (95% CI 12.5,20.8).
RSV transmissibility potential
In order to provide useful insight on the transmissi-
bility potential of RSV in the considered population a
range of possible reproductive numbers based on the pro-
posed transmissionmodel and on the parameter estimates
obtained by model calibration were computed.
In particular, we first compute the basic reproduction
number R0 and the effective reproductive number Re,
which are respectively defined as the average number
of individuals infected by a typical infectious individual
in a fully susceptible population and when a fraction of
the population is - at least partially - protected against
the infection. Second, the transmission potential of RSV
infection has also been investigated by computing the
Rindex and the Rindexe which are respectively defined as
the average number of individuals infected by the first
infectious individual (the index case) in a fully suscep-
tible population and in a partially immune population.
The procedures adopted for computing R0,Re,Rindex, and
Rindexe are detailed in Additional file 1.
Results are summarized in Figure 2c. We found that R0
is 2.18 (95% CI 1.49,3.24), Re is 2.0 (95% CI 1.48,2.91),
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Figure 1 RSV transmission patterns A. Distribution (2.5%, 25%, 75%, and 97.5% quantile and mean) of incidence of primary (a) and repeated (b)
RSV infection by age, simulated (blue) and observed (red) in a birth cohort of children followed for three RSV seasons in Kilifi, Kenya [4]. Data credible
intervals were computed through exact binomial test. (c) Distribution (2.5%, 25%, 75%, and 97.5% quantile and mean) of simulated (blue) and
observed (red) age-specific RSV IgG seroprevalence within the followed cohort after three RSV seasons [4]. (d) Distribution (2.5%, 25%, 75%, and
97.5% quantile and mean) of simulated incidence of RSV infection by age.
Rindex is 1.65 (95% CI 1.03,2.66), and Rindexe is 1.57 (95% CI
1.02,2.39). Values obtained for Rindex and Rindexe are lower
than those for R0 and Re as the initial infective individual
is randomly chosen and therefore it cannot be considered
a “typical” infector, as required in the definition of R0 and
Re. The obtained difference between the estimated Re and
Rindexe is in line with literature values [35,36] and estimates
of R0 and Re do not remarkably change when importation
of new cases is not considered in model simulations.
The obtained estimates of the RSV transmission poten-
tial are in satisfactory agreement with independent esti-
mates obtained elsewhere by using an SIRS model (that
is, with no partial lifelong immunity) [24]. In addition, by
computing the average number of individuals infected by
the first infectious individual in a partially immune popu-
lation within her/his household we inferred the chance of
observing a household outbreak after the introduction of
RSV in a household. Our results suggest that a randomly
sampled index case produces on average 0.50 case (95%
CI 0.41,0.55) within the household, therefore resulting in
a household outbreak in 50% of cases. This estimate is in
line with results obtained in [Munywoki et al. 2014] where
out of 73 separate RSV introductions into households,
only 32 (43%) generated a household outbreak.
Finally, estimates of R0, Re, Rindex, and Rindexe are lower
when no transmission in schools is assumed (for example,
when schools are closed). This suggests that schools and
students play a relevant role in the transmissibility of RSV
in the population. This is supported by the investigation
of Rindexe stratified by age classes which highlight that the
Rindexe of students is 67% higher than the average Rindexe ,
but that it is reduced by 40% when schools are closed.
The RSV transmission chain: the role played by households
and school-age children
In agreement with a recent epidemiological study which
investigated the role of household transmission in a
rural community in the Kilifi district [15], we found
that the percentage of infant primary infections gener-
ated by household transmission in a specific subgroup of
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Figure 2 RSV transmission patterns B. (a) Simulated proportions of transmission occurring at home and at school stratified by age class. Vertical
lines represent 95% credible intervals. (b) Simulated age-specific ratio between the probability of being an index case in a household outbreak over
the probability of being the first secondary case generated by household transmission. Shaded area represents 95% credible intervals. (c)
Transmissibility potential of RSV. (d) Percentage of infection episodes generated through household transmission due to contacts occurring
between individuals of different ages.
households (see [15] for details) is on average 49.5% (CI
95% 41.0,58.5) (versus 53% in [15]). Such results refer to
a set of households chosen among those with at least one
infant and one or more older siblings under 13 years of age
[15].
By extending our analysis to all types of households and
by accounting for both primary and repeated infections,
we found that, on average, 38.3% (CI 95% 35.4,40.9) of
infants and 38.6% (95% CI 37.4,40.0) of children under 5
years of age contract RSV as a consequence of contacts
occurring within households. On the other hand, among
older children (5-10 years), where school attendance rates
are high (see Additional file 1), school transmission is pre-
dicted to be responsible for about 30% of RSV infections
(see Figure 2a).
The contribution of household contacts to overall
RSV transmission (that is, irrespective of age) increases
with household size. For instance, while 33.0% (95% CI
32.4,33.4) of transmission in the overall population occurs
in the household, if we restrict our analysis to house-
holds of two individuals, the resulting average proportion
of cases generated within the household is less than 12%,
while it is about 35% when considering households with
ten individuals or more (details are reported in Additional
file 1).
Our analysis allows the identification of individuals who
introduce the infection into the households (index cases)
as well as the first cases generated by household con-
tacts (secondary cases). We found that, on average, 54.6%
(CI 95% 41.6,65.8) of index cases responsible for a house-
hold outbreak were school-age children. Moreover, the
role played by different age categories in introducing RSV
into households was highlighted by computing for each
age the ratio between the probability of being an index
case and the probability of being the first secondary case
generated by household transmission. The resultant ratio
is presented in Figure 2b and shows that school-age chil-
dren are, on average, up to 50% more likely to be index
cases than first secondary cases.
We further investigated household transmission by
recording, for each case generated within households,
both the age of the infected individual and the age of its
infector. Figure 2d aims to highlight where (in terms of
ages) most of the infections occur by showing the propor-
tion of incidence of within household transmission due to
contacts occurring between individuals of different ages.
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Specifically, in Figure 2d matrix Mi,j is reported, where
Mi,j = 100 · Ci,j/∑i∑j Ci,j and Ci,j is the recorded num-
ber of household infection episodes where an individual
of age i was infected by an individual of age j.
Our results show that most of the transmission occurs
between siblings of similar age and between parents and
their children. However, school-age children are predicted
to be the main source of household transmission, caus-
ing approximately 55% of all RSV cases generated within
household and 40% of infant cases. This indicates that vac-
cination of school-age children might represent a valuable
strategy for decreasing the occurrence of infection within
households and, in turn, among infants.
Preventing RSV in infants with short-lived vaccine
immunity
The impact of different immunization strategies was eval-
uated in terms of predicted reduction of the infection
incidence among infants and in the general population,
the number of vaccine doses administered, and the age at
first infection. These outcomes have been analyzed 1 and
10 years from the start of vaccination. In Figure 3 the esti-
mated impact of the most effective vaccination strategies
is shown assuming a vaccination coverage of 100% and a
vaccine protection that lasts 6 months, which reflects the
estimated duration of immunity provided by natural infec-
tion (the impact of the remaining strategies is shown in
Additional file 1).
Our results show that routine immunization at 3
months of age and annual repeated vaccination of all stu-
dents are the only two strategies able to trigger a relevant
and persistent reduction of RSV infection occurrence in
infants. Specifically, in 10 years of vaccination, the for-
mer strategy is predicted to reduce RSV infant infection
incidence by 41.5% (95% CI 40.2,63.8) with little impact
on the other age groups, while the latter strategy is pre-
dicted to generate a reduction of 35.6% (95% CI 13.7,89.4)
in infants and 48.0% (95% CI 23.1,85.4) in the general pop-
ulation. The benefits resulting from catch-up campaigns
performed in the first year of vaccination completely wane
after a few years (less than five), and require a signifi-
cant increase in the number of administered vaccines (see
Figure 3 and Additional file 1).
Although repeated vaccination of students entails a rel-
atively high number of annually administered vaccines,
namely 0.19 dose per person per year, this strategy is
expected to be the most valuable alternative to infant
immunization if RSV vaccines would not be suitable to
be administered safely to infants. In addition, by employ-
ing this immunization strategy, the median age at first
infection is expected to increase significantly, from 16.0
months to 21.0 months on average (see Additional file 1),
possibly leading to a reduction in the incidence of severe
disease.
It is worth noting that vaccination targeting only stu-
dents (or new students) cohabiting with infants is not
enough to break the RSV transmission chain leading to
infant infection, entailing only negligible delays in the
median age at first infection (see Additional file 1).
The potential benefits of longer vaccine immunity
The estimated impact of different immunization strategies
after 10 years of vaccination under different assumptions
on the duration of vaccine-induced immunity and on the
fraction of successfully immunized individuals in the tar-
get population is summarized in Figure 4. Our results
show that if the vaccine can induce longer protection than
natural infection, all the considered strategies perform
better, and some additional immunization strategies have
the potential to remarkably reduce RSV infant infections.
Specifically, when the administration of a vaccine to preg-
nant women is able to boost natural maternal antibodies
to 8 months of protection against RSV infection in their
offspring (extending maternal protection by 4 additional
months), the strategy of targeting future mothers can be
considered an additional and valuable alternative to the
direct immunization of infants, resulting in a reduction in
the RSV infant incidence of 31.5% (95% CI 30.7,37.5). In
contrast, if newborns will benefit only from the (indirect)
herd immunity effect, immunization of pregnant women
is not expected to prevent RSV infection in infants (see
Additional file 1). In comparison, when vaccine-induced
immunity lasts 1 year, the routine immunization at 3
months of age and the annual repeated vaccination of all
students can be considered similarly effective, leading to
a reduction in RSV infant incidence ranging, on average,
from 62.9% to 69.1%.
Unfortunately, for a vaccine-induced immunity shorter
than the protection provided by natural infection (for
example, 4 months), the ability of the latter strategies
to prevent RSV infection in infancy is markedly reduced
(see Figure 4). Indeed, in this case, the expected aver-
age reduction of RSV infant incidence after 10 years of
vaccination with routine immunization and annual vacci-
nation of students ranges between 23.4% and 24.2%, on
average.
The scenario of sub-optimal coverage
If the fraction of successfully immunized individuals in the
target population is reduced - as a consequence of either
a lower vaccine coverage or a limited vaccine efficacy -
the expected reduction in RSV incidence among infants
and in the general population achieved after 10 years
of vaccination decreases for all the considered strategies
(see Figure 4). However, if the vaccine-induced immu-
nity lasts 1 year, even when only 60% of the targeted
population is protected, routine immunization of infants
and repeated vaccination of all students are predicted to
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Figure 3 Impact of vaccination strategies: baseline scenario. Average number of administered vaccine per person per year (top row),
distribution (2.5%, 25%, 75%, and 97.5% quantile and mean) of RSV incidence in infants (middle row), and in the general population (bottom row) as
predicted by model simulation before vaccination (year 2014) and 1 and 10 years after vaccination (years 2015 and 2025) associated with the most
effective vaccination strategies. Vaccine protection against infection is assumed to last 6 months and vaccination coverage is 100%. Vaccination of
pregnant women is assumed to extend natural maternal protection of newborns from 4 to 6 months. The gray line reported throughout is used as a
reference indicator for the no vaccination scenario.
reduce infant RSV incidence by on average 39.6% and
45.6%, respectively, after 10 years of vaccination.
In contrast, the effectiveness of newborn immuniza-
tion through vaccination of pregnant women seems to
be only slightly affected by sub-optimal coverage. Indeed,
under all assumptions on the duration of vaccine-induced
immunity, when the fraction of protected infants through
vaccination of pregnant women is 60%, the reduction of
RSV infections in infants is predicted to be at most 4%
lower than what could be achieved with 100% coverage
and a fully effective vaccine. The robustness of this strat-
egy is especially relevant considering that the delivery
of a vaccine through antenatal care may be sub-optimal
because of possibly low women attendance rates to ante-
natal clinics, and also in terms of protection because
of premature births. This means that, if a vaccine able
to significantly boost maternal protection of newborns
through vaccination of pregnant women would be avail-
able, this strategy might possibly represent the best trade-
off between the ability of preventing RSV in infants and a
limited number of doses required.
Conclusions
Although vaccine development aimed at prevention of
RSV disease in young children dates back to the 1960s, and
several trials are ongoing to identify a suitable candidate
product, no vaccine has been licensed yet [14]. A better
understanding of the RSV transmission chain leading to
infant infection can be critical to the selection of suitable
candidate vaccines and population targets [14,37].
With this objective in mind, we have developed an
individual-based model for investigating RSV transmis-
sion patterns in a low-income setting of rural coastal
Kenya. The chosen modeling framework has allowed
us to disentangle the contribution of different social
settings in the spread of the infection in the popula-
tion, to characterize the transmission chain leading to
RSV infant infections, and to investigate the impact of
a range of immunization schedules that are plausible
alternatives to routine early infant vaccination. Specifi-
cally, these options include vaccination of school chil-
dren, siblings of susceptible naive infants, and pregnant
women.
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Figure 4 Impact of vaccination strategies: alternative scenarios. Distribution (2.5%, 25%, 75%, and 97.5% quantile and mean) of RSV incidence
in infants (red) and in the general population (blue) and the average number of administered vaccines per person per year (orange) as predicted by
model simulation after 10 years of vaccination for 3 selected strategies under different assumptions on the duration of vaccine protection (4
months, 6 months, and 1 year) and on the percentage of successfully immunized individuals in the target population (100%, 80%, and 60%). Gray
lines reported in the plots represent the average value predicted for the no vaccination scenario. In the scenario in which vaccine protection of
newborns results from vaccination of pregnant women, 5, 6, and 8 months duration represent extended durations due to vaccine boosting of 1, 2,
and 4 months, respectively.
Our analysis determined household transmission to be
responsible, on average, for about 39% of infant infec-
tions and found that school-age children play a key role
in introducing RSV infection into the household, caus-
ing about 55% of household outbreaks. Moreover, our
results showed that RSV infection provides complete nat-
ural immunity against reinfection for a period of around 6
months, after which resistance to reinfection appears very
limited.
The vaccination strategies considered are shown to
reduce RSV infection incidence both in infants and in
the general population in different ways, and their impact
critically depends on the duration of vaccine-induced
protection. However, model predictions robustly suggest
that as an alternative to direct vaccination of very young
children, prevention of RSV in infancy can be achieved
by reducing the transmission in the general population
through the vaccination of students. In particular, in the
case of a short-lived vaccine-induced immunity, for exam-
ple, 6 months, the annual vaccination of all students is
predicted to be the most valuable alternative to the direct
immunization of young infants, reducing RSV infection
occurrence in those less than 1 year of age by more than
35% after 10 years of vaccination, as opposed to a 41%
reduction of infant infections when directly targeting 3-
month-old babies. Additionally, a maternal vaccine able
to increase the average duration of passive RSV protec-
tion by only 4 months represents an effective strategy for
preventing RSV occurrence in infancy, even in the case
of sub-optimal coverage. In particular, in this case, our
results show that RSV infant infection incidence could be
reduced through vaccination of pregnant women by at
least 30%.
In conclusion, our results robustly show that school-
age children should be considered for alternative effec-
tive vaccination programs in case direct immunization
of high-risk infants is not achievable. In addition, vac-
cination of pregnant women also has the potential of
being an effective strategy. Clearly, for strategies target-
ing the transmitters of infection rather than those most
vulnerable to disease following infection, education of the
public will be a priority to ensure the acceptability and
sustainability of such immunization programs [32,38].
Finally, note that in this work there is no attempt to
quantify the impact of vaccination on the risk of dis-
ease following infection. Since the changes in incidence
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predicted are accompanied by changes in the age distri-
bution of infection (to a degree varying by strategy), and
because the risk of disease is highly dependent on age at
infection, then the outcomes of vaccine impact on infec-
tion and on disease are not directly proportional. Thus, for
example, the effect of repeated vaccination to school age
children with large effect on age at infection would result
in a proportionally higher effect on RSV disease. Also, the
effect of maternal vaccination and increased duration of
passive immunity in infants would directly protect those
most at risk of severe disease, and so the impact on dis-
ease would be more significant than the reported impact
on infections.
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